SCHEMBL6737940

SCHEMBL6737940

Cc1ccc(CO[C@H](c2nccs2)C(CO)NS(=O)(=O)c2ccc(Br)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
ALDH1A1 P00352 5/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
POLB P06746 3/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
CYP2C9 P11712 1/20 0.37
PPIA P62937 1/20 0.36
CA1 P00915 3/20 0.35
CA2 P00918 3/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
PKM P14618 2/20 0.35
MAPK10 P53779 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.35
MMP14 P50281 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6737939 1.00 EGFR (0.40) EGFRERBB2ALDH1A1CYP3A4CYP2C19
SCHEMBL6733702 0.85 EGFR (0.41) EGFRERBB2ALDH1A1POLBMEN1
SCHEMBL6733656 0.74 ADAMTS4 (0.58) MMP2MMP9MMP14
SCHEMBL6738316 0.74 ADAMTS4 (0.51) EGFRPKMMMP2MMP9MMP14
SCHEMBL6733010 0.74 MMP2 (0.50) MMP2MMP9MMP14
SCHEMBL7389687 0.73 MMP2 (0.43) ALDH1A1PKMMMP2MMP9MMP14
SCHEMBL6732124 0.73 MMP2 (0.43) ALDH1A1PKMMMP2MMP9MMP14
SCHEMBL6742787 0.73 ALDH1A1 (0.38) ALDH1A1CYP3A4CYP2C19MEN1KMT2A
SCHEMBL7385883 0.69 ALDH1A1 (0.41) EGFRERBB2ALDH1A1POLBMEN1
SCHEMBL3185795 0.66 MMP2 (0.55) ALDH1A1CYP3A4CYP2C19CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040142975-A1 Beta disubstituted metalloprotease inhibitors THE PROCTER &GAMBLE COMPANY 2004-07-22 US disclosed
US-6696456-B1 CARBOCYCLIC ACIDS AND SALTS SUCH AS (2S,3R)-3-ETHYLSULFANYL-2-(4'-FLUORO-BIPHENYL-4-SULFONYLAMINO)-3- PHENYLPROPIONIC ACID, USED AS METALLOENZYME ANTAGONISTS FOR THE PROPHYLAXIS OF DEGENERATIVE JOINT DISEASE AND AS WOUND HEALING AGENTS THE PROCTER & GAMBLE COMPANY 2004-02-24 US disclosed
EP-1224171-A1 BETA DISUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2002-07-24 EP disclosed
WO-2001027084-A1 BETA DISUBSTITUTED METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142975-A1 Beta disubstituted metalloprotease inhibitors ADAM17, ADAM9, SI EGFR 1593/4885ERBB2 3395/4885ALDH1A1 317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.